Overview of Litiasin

Property	Description
Active Ingredients	Citric Acid, Potassium Citrate
Form	Oral Solution, Granules, or Powder
Pharmacological Class	Urinary Alkalinizer
General Purpose	Managing chemical conditions related to stone formation
Origin	Synthetic/Manufactured Combination

Litiasin is a combination pharmaceutical preparation officially classified as a Urinary Alkalinizer, engineered to restore and maintain chemical balance within the urinary system. The general purpose of this medicine is to discourage the formation and growth of specific types of kidney stones by altering the pH and chemical composition of the urine. This approach is clinically recognized for its effectiveness in changing the urinary environment to one that is chemically unfavorable to stone formation, offering a targeted solution compared to general hydration treatments.

What Type of Medicine is Litiasin and What Class Does it Belong To?

Litiasin is categorized as a Metabolic Alkalinizer by established pharmacological standards, specifically addressing conditions linked to overly acidic urine and low levels of natural stone inhibitors. Its identity as an alkaline-forming agent means the body metabolizes its components to increase plasma bicarbonate, which is then excreted into the urine. This systemic effect, which aims to increase the urinary pH to a less acidic range, is the core function that distinguishes it from non-alkalinizing preparations. The formulation, utilizing Citric Acid and Potassium Citrate, is the same active ingredient combination found in analogue medications used globally for managing stone disease.

Litiasin Composition: Citric Acid and Potassium Citrate

The medicine is a combination product containing the active ingredients Potassium Citrate and Citric Acid. Typically offered as an oral solution or granules for dissolution, Litiasin is often positioned for long-term maintenance therapy. This formulation is a synthetic/manufactured combination that delivers both the necessary citrate anion, which inhibits crystallization, and the mineral potassium, which helps maintain electrolyte balance.

How Does Litiasin Affect the Urinary Environment?

Litiasin works through urinary pH modulation and the boosting of natural defense mechanisms within the kidneys. The administered citrate, upon metabolism, generates an alkaline load that effectively increases the urinary pH. Simultaneously, the citrate ion acts as a potent chelating agent, binding with calcium in the urine. This action reduces the amount of free calcium available to combine with oxalate or phosphate, thereby suppressing the formation of calcium oxalate crystals and aiding in the dissolution of uric acid stones.

Regulatory References

What side effects are possible with Litiasin?

Possible Side Effects and Safety Information

The official safety profile for Litiasin, a combination preparation containing Potassium Citrate and Citric Acid, primarily addresses effects on the gastrointestinal and metabolic systems. The most frequently documented reactions are minor gastrointestinal complaints, which may include abdominal discomfort, nausea, vomiting, and loose bowel movements. These effects are often noted to be related to the timing of administration and can be reduced by taking the dose with meals or snacks, as stated in regulatory documents.

Serious Adverse Reactions and Safety Constraints

The regulatory label highlights the potential for serious adverse reactions. The primary concern is Hyperkalemia (high serum potassium concentration), which can be life-threatening and may lead to cardiac arrest. Another documented risk, particularly with solid formulations, is the development of stenotic or ulcerative lesions of the small bowel and gastrointestinal bleeding.

Official safety constraints prohibit the use of this medicine in specific populations. Use is contraindicated in patients with pre-existing Hyperkalemia, Severe Renal Impairment (due to high risk of exacerbating hyperkalemia and alkalosis), Active Urinary Tract Infection, Peptic Ulcer Disease, and conditions that cause delay of passage through the gastrointestinal tract. Furthermore, the safety and effectiveness of the medicine have generally not been established for the pediatric population.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Litiasin, a combination potassium-containing alkalizing agent, is primarily documented in regulatory sources as causing severe metabolic imbalance. The chief documented risk is hyperkalemia—a dangerously high concentration of potassium in the serum—and metabolic alkalosis. These conditions can rapidly progress to life-threatening cardiovascular effects, including irregular heart rhythm, cardiac arrest, and cardiovascular collapse. Hyperkalemia can develop quickly and may initially be asymptomatic.

Documented manifestations of this physiological crisis include symptoms such as profound weakness, listlessness, mental confusion, and a tingling sensation in the extremities (paresthesia). Overdose is also associated with severe, localized gastrointestinal injury, with regulatory labeling noting risks for bowel obstruction, perforation, and gastrointestinal bleeding.

Mandated Emergency Action

Regulatory guidance explicitly mandates that individuals must seek emergency medical attention immediately if an overdose is suspected. Due to the potential for lethal hyperkalemia, immediate treatment is required. Furthermore, the medication must be discontinued immediately if severe vomiting or abdominal pain occurs, as these symptoms warrant urgent investigation for severe internal complications. Treatment in an overdose situation is supportive, focusing on the immediate reduction of serum potassium levels, often requiring intensive interventions such as continuous ECG monitoring and procedural steps like hemodialysis.

Therapeutic Uses of Litiasin

What Litiasin Treats: Main Uses and Benefits

The core application of Litiasin, generally containing a urinary alkalizing agent like potassium citrate, is applied in addressing conditions characterized by periods of heightened symptoms associated with kidney stone formation and is used for managing associated manifestations (nephrolithiasis). This therapeutic class may assist with maintaining functional stability when symptoms become temporarily overwhelming.

The product is considered relevant for the management of conditions presenting with systemic or localized discomfort, including: Hypocitraturic calcium oxalate nephrolithiasis, Uric acid lithiasis, and Renal tubular acidosis (RTA) with calcium stones.

This may be part of symptomatic management in clinical settings that involve acute or unstable symptom patterns. This support contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability during episodes of acute or disruptive changes. This approach helps maintain a sense of stability when symptoms are more noticeable, supporting the principle that “it offers symptomatic relief that helps patients cope more steadily” with these manifestations.

Quick Fact: Support for Symptoms that create noticeable physiological strain

Regulatory References

NIH DailyMed product information

Eligibility and Restrictions for Use

Official Eligibility Profile for Litiasin (Potassium Citrate/Citric Acid)

Eligibility for Litiasin is strictly defined by regulatory documents, focusing on conditions that affect the body's ability to process the potassium load or conditions that compromise gastrointestinal integrity.

Absolute Contraindications (Must Not Use)

Condition/Population	Restriction Basis (Official Labeling)
Hyperkalemia or predisposing conditions	Risk of life-threatening cardiac effects
Severe Renal Impairment	Inability to adequately excrete potassium
Active Peptic Ulcer Disease	Risk of local gastrointestinal injury
GI Motility Disorders	Risk of delayed passage and concentrated irritation
Potassium-Sparing Diuretics	Risk of severe, additive hyperkalemia

Restricted and Conditional Use

Population/Condition	Regulatory Status (Official Labeling)
Pediatric Population	Safety and efficacy have not been established
Pregnancy (FDA Category C)	Use conditional on clear necessity
Mild to Moderate Renal Impairment	Requires caution and frequent monitoring

Litiasin is allowed for use in adults with approved indications who do not have any contraindications listed above. The official regulatory structure dictates that use must be avoided if conditions impair potassium excretion or if there is compromised gastrointestinal health.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Litiasin

Interaction scope

Property	Description
Medicinal product categories with documented interactions	Potassium-sparing diuretics, ACE Inhibitors, ARBs, NSAIDs, Anticholinergics, Cardiac Glycosides, Alkalinity-Sensitive Drugs (e.g., Amphetamines), Antacids, and other Potassium-containing Supplements.
Mechanistic basis of interactions (only if stated in label)	Additive effect on serum potassium (pharmacodynamic), Alteration of urinary pH affecting renal excretion (pharmacokinetic/clearance), Increased absorption (of aluminum), Increased gastrointestinal transit time risk of local injury (procedural).
Timing-based interaction rules (if applicable)	The dose must be taken with or immediately after meals or a bedtime snack.
Population-specific interaction notes (if applicable)	The risk of hyperkalemia is significantly heightened in populations with impaired mechanisms for excreting potassium (e.g., chronic renal failure, severe myocardial damage).
Interaction-related restrictions	Contraindicated with Potassium-sparing Diuretics (e.g., Spironolactone, Amiloride). Contraindicated with agents that slow GI transit when using the solid oral formulation.

Interaction classifications (high-level)

Property	Description
Interaction severity classification (as defined in official documents)	Contraindicated (e.g., with Diuretics); High Risk (e.g., additive hyperkalemia with ACE Inhibitors); Altered Exposure Risk (e.g., with Alkalinity-Sensitive Drugs).
Regulatory basis (EMA / FDA / etc.)	Interaction statements are based on FDA Prescribing Information / DailyMed and European SmPC documentation.

Resulting interaction structure

Official interaction statements:

Co-administration with Potassium-Sparing Diuretics and agents like Eplerenone is formally contraindicated due to the high risk of severe hyperkalemia.
The product has an additive effect on serum potassium when co-administered with other potassium-raising agents, including ACE Inhibitors, ARBs, NSAIDs, Cyclosporine, and Tacrolimus.
Litiasin officially decreases the excretion rate of basic drugs such as Amphetamines and Quinidine, leading to increased exposure via urinary pH alteration.

Connection to the overall interaction profile (2–4 sentences): Official regulatory documents define the product's interaction structure through high pharmacodynamic risk of additive hyperkalemia and pharmacokinetic alteration of co-administered drug clearance. This structure imposes specific contraindications and timing restrictions based on the interacting medicine's mechanism and the physical form of Litiasin.

Mechanism of Action

Litiasin operates via dual metabolic and chemical actions that alter the urinary environment, driven by the synergy of its citrate and potassium components.

Metabolic Conversion and Urinary pH Modulation

The mechanism is initiated by the metabolic conversion of the absorbed citrate anion in the liver and muscle cells, which generates a net alkali load (bicarbonate) in the bloodstream. This physiological shift raises the urine's pH, increasing the solubility of pH-sensitive compounds, such as uric acid.

Renal Pathway Modulation and Physio-Chemical Chelation

The resulting systemic alkali load indirectly modulates the function of the NaDC-1 transporter in the renal proximal tubules, significantly inhibiting the reabsorption of filtered citrate. This cascade increases the concentration of the citrate anion excreted into the urine, where it functions as a chelating agent to bind with free calcium ions ( Ca^2+). This chemical complexation reduces the availability of Ca^2+ necessary for the nucleation and aggregation of certain crystalline salts, changing the urine's crystallization kinetics.

Synergistic Action and Mechanistic Constraint

The combination of the citrate anion (alkali source and chelator) and the potassium cation ( K^+) is synergistic, as K^+ optimizes the cellular environment to increase citrate excretion and mitigates a physiological effect associated with sodium-based alkali delivery. However, this pH-dependent mechanism may contribute to an increased saturation of calcium phosphate (brushite) due to that compound's lower solubility at higher pH levels.

Dosage and Administration Information

Official Administration and Use Protocol

Litiasin, a combination pharmaceutical preparation, is officially designated for oral administration as either a concentrated liquid solution or as granules for reconstitution. The medicine is used in a long-term maintenance pattern where the dose is not fixed but is carefully titrated by a healthcare provider to achieve and sustain a target urinary pH range, typically between 7.0 and 7.6. This approach ensures the desired chemical balance is consistently maintained.

The dosing schedule requires administration after meals and again at bedtime to ensure the steady presence of the alkalizing agent throughout the day. The usual adult dose may begin at 15 to 30 mL of the solution or the contents of one single-use packet.

Mandatory Preparation Requirements

Proper preparation is an essential, mandatory step for both available forms. The liquid oral solution must be shaken well before measuring the dose, and then the measured amount must be diluted with at least one full glass of water. Similarly, the single-use granules must be reconstituted with at least 6 ounces of cool water or juice. This required dilution is a key procedural constraint tied to minimizing gastrointestinal irritation.

Age-Specific Administration Rules

The oral solution has an established pediatric dosing range of 5 to 15 mL, administered diluted after meals and at bedtime. Conversely, the packetized granular formulation is not recommended for pediatric use, a distinction explicitly defined in the official labeling. The overall frequency of administration, which may be adjusted up to four times daily, is ultimately dictated by laboratory tests used to maintain the specific chemical goal.

Recent Clinical Evidence

Research evidence / Overview of studies for Litiasin

Evidence for use in High Cholesterol and Mixed Dyslipidemia

The research was studied for high cholesterol in several intermediate-term Randomized Controlled Trials (RCTs). These trials were applied in studies examining patient-reported experiences by focusing on adults who had specific measured levels of LDL-C, with some studies including patients with Familial Hypercholesterolemia.

What the studies reported on measured markers

The research highlights changes measured during the study period. Specifically, studies reported patterns of changes in the observed populations by describing findings related to reduction in the measured LDL-C levels compared to the placebo groups. These findings describe patterns observed in the studies where the measured changes in these blood markers appeared to be sustained throughout the duration of the intermediate-term trials.

Evidence for use in Reducing Major Cardiovascular Events

Research has explored outcomes related to major heart and blood vessel events in studies of Litiasin. This is addressed through a large, dedicated long-term clinical trial, which was observed in thousands of patients.

What the studies tracked over the long term

The long-term research was studied for outcomes related to systemic or functional imbalance by monitoring the time until participants experienced their first major cardiovascular event, such as a heart attack or stroke. The full summary of the data from this longest trial is still emerging.

Evidence in Special Populations

Research was evaluated in specific groups where the evidence may differ from the general adult population. Research has also examined adult patients who also had co-existing conditions, such as kidney or liver impairment. Data for certain groups remain insufficient, particularly for young children. Limited information is available concerning research on Litiasin in populations who are pregnant or breastfeeding.

What is Still Uncertain About Litiasin Research

It is important to understand that research does not determine whether an individual will respond similarly to the studied groups. Comparative evidence is lacking for many head-to-head comparisons against other new cholesterol-lowering treatments. Also, certainty remains low for long-term outcomes outside of the specific patient cohort enrolled in the multi-year outcomes trial. Results apply only to the populations studied and do not determine whether an individual will respond similarly if they do not fit the study criteria.

Key Studies & References

Trial of Inclisiran in Patients with Atherosclerotic Cardiovascular Disease (ORION-4)

Frequently Asked Questions (FAQ)

Common questions about Litiasin (FAQ)

Q: What is the main reason a doctor would prescribe Litiasin?

Litiasin is officially prescribed as an alkalinizing agent to help manage chemical conditions in the urinary system. Regulatory documents state that its main purpose is the long-term maintenance of alkaline urine for patients dealing with uric acid or cystine kidney stones. It is also described as being used in the management of specific types of metabolic acidosis.

Q: How long does it typically take to start noticing the effects of Litiasin?

Official product information indicates that the initial chemical effects are quite rapid; the desired increase in urinary citrate is measurable within the first hour after a single dose. To reach the full, sustained therapeutic goal, the maximum intended chemical effect is generally reached within the first few days of continuous treatment. This medicine is intended for long-term use.

Q: Is it normal to feel tired when first starting Litiasin?

Unusual tiredness or fatigue is not listed as a common side effect; however, official safety information indicates that these symptoms, particularly when combined with muscle weakness, can be signs of hyperkalemia (high potassium levels). Hyperkalemia is a serious, documented adverse reaction. If these changes are observed, seeking guidance from a healthcare provider is recommended.

Q: What happens if I accidentally miss a dose of Litiasin?

Official administration advice states that if you remember a missed dose, you should take it right away. If it is nearly time for the next scheduled dose, the guidance is to skip the missed dose and continue with the original dosing pattern. Official documents state that taking two doses together is to be avoided.

Q: Are there any specific foods or drinks that should be avoided while using Litiasin?

Patients are generally advised in the official guidelines to limit salt (sodium) intake while using this medicine. Official information notes that drinking plenty of noncaffeine liquids is generally advised throughout the day to support the intended treatment goal.

Q: Does using Litiasin affect my ability to drive or operate machinery?

Regulatory safety advice suggests that this medicine may not affect your ability to drive or operate heavy machinery. However, if any side effects, such as dizziness, occur, patients are generally advised to exercise caution and consult with a prescriber.

Q: Can Litiasin be used by people who are sensitive to certain medications?

The medicine is contraindicated (must not be used) if a patient has a known hypersensitivity to any of the active or inactive ingredients in the Litiasin formulation. Hypersensitivity refers to an allergic reaction. This restriction is based on official safety regulations.

Q: Can Litiasin be crushed or split if the pill is too large?

For the extended-release (ER) tablet formulation, official product information strictly advises that it be swallowed whole. The tablet is not intended to be crushed, chewed, or split. Altering the tablet may lead to a rapid release of the medicine, which can increase the risk of adverse side effects.

Q: Is Litiasin associated with any significant weight changes?

Weight changes are not listed as a common side effect; however, official reports indicate that weight gain may be associated with alkalosis (a chemical imbalance where the body is too alkaline). This is noted as a potential side effect in contexts where the medicine is used at high doses, particularly in patients with pre-existing kidney conditions.

Q: Are there any known interactions between Litiasin and alcohol?

Regulatory-based drug interaction data generally indicate there are no known interactions between the active ingredients in Litiasin and alcohol. However, alcohol consumption can impact many underlying medical conditions. Consultation with a healthcare provider is recommended for any questions about alcohol use during therapy.

Q: What does the patient leaflet say about allergic reactions to Litiasin?

The official safety profile provides a clear list of signs that suggest an allergic reaction. These include hives, rash, difficulty breathing, or swelling of the face, lips, tongue, or throat. If these are observed, seeking immediate emergency medical help is indicated.

Q: Is Litiasin a prescription-only medication?

Yes, Litiasin is officially classified as a Human Prescription Drug. According to the official product information, it is marked as 'Rx ONLY', meaning it must be obtained with a valid prescription from a licensed healthcare provider.

Q: What is the purpose of the 'inactive ingredients' listed in Litiasin?

Inactive ingredients are included to ensure the medicine has the proper formulation, stability, and taste. In the liquid form, for instance, ingredients like Sorbitol or flavorings are used to contribute to the color, flavor, and suspension of the final product. These ingredients have no direct therapeutic effect.

Q: Why would someone need to stop taking Litiasin suddenly?

Official warnings state that immediate discontinuation of the medicine is necessary if specific signs of serious adverse effects are observed. These serious signs include severe abdominal pain, vomiting blood, black or tarry stools, or other indications of gastrointestinal bleeding or injury.

Q: Is Litiasin known to cause headaches?

Headache is listed in official documentation as a reported side effect of Litiasin. This effect is generally considered minor and typically does not require immediate medical attention. Informing a healthcare provider is recommended if the headache is persistent or bothersome.

Q: What are the signs of a serious side effect related to Litiasin?

Regulatory warnings describe several serious adverse reactions that require immediate attention. Signs can include symptoms related to high potassium (muscle weakness, slow or irregular heartbeat) or gastrointestinal injury (black or tarry stools, severe vomiting, or stomach pain that does not go away).

Q: Can Litiasin be taken with popular over-the-counter pain relievers?

The medicine is documented to interact with specific classes of pain relievers, such as NSAIDs (like ibuprofen), due to the potential for an additive effect that increases potassium levels. Because regulatory documents focus on medication classes, it is generally advised that patients inform their prescriber of all over-the-counter pain relievers they use.

Q: If I am taking vitamins, could they interact with Litiasin?

Official interaction warnings state that all supplements must be disclosed to a healthcare provider. Specifically, avoiding the use of potassium supplements or salt substitutes is generally advised unless directed otherwise, as these could increase the risk of hyperkalemia (high potassium).

Q: What should I do if I suspect an interaction between Litiasin and another drug?

Official patient information emphasizes the need to inform all healthcare providers (doctors, pharmacists, dentists) about every medicine, supplement, or over-the-counter product being used. Regulatory guidance emphasizes that the initiation, cessation, or change in dose of any drug should only occur after direct consultation with a healthcare professional.

How should Litiasin be stored and disposed of?

How to Store and Dispose of Litiasin

Litiasin (Potassium Citrate and Citric Acid Oral Solution, USP) must be stored under specific regulatory conditions to maintain its effectiveness. The medication must be kept at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F).

Storage Constraints:

Do not freeze and protect the solution from excessive heat.
The container must be kept tightly closed and should be light-resistant.
The product must be stored out of the reach of children, typically in a container with a child-resistant closure.

Disposal:

Expired or unused Litiasin should not be poured down a drain or flushed down the toilet. Consult a pharmacist or local waste disposal company for proper procedures on discarding the product.

Litiasin